Amphastar Pharmaceuticals Director Buys $40,080 in Stock (AMPH)
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Richard K. Prins bought 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was purchased at an average price of $10.02 per share, with a total value of $40,080.00. Following the acquisition, the director now directly owns 36,051 shares in the company, valued at approximately $361,231. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
AMPH has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 10.08 on Thursday. Amphastar Pharmaceuticals has a one year low of $6.67 and a one year high of $11.07. The stock’s 50-day moving average is $9.40 and its 200-day moving average is $9.4. The company’s market cap is $437.5 million.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.13. Analysts expect that Amphastar Pharmaceuticals will post $-0.17 EPS for the current fiscal year.
Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.